American Society of Nephrology establishes new foundation

It is time for a cure.

Fighting and curing kidney disease, the 8th leading cause of death in America, requires the best and brightest minds in medicine and research to apply creativity, time and expertise to this major public health concern.

The American Society of Nephrology (ASN) has announced the creation of a new foundation—the ASN Foundation for Kidney Research—to propel major research advances in the treatment of kidney patients, and reach a cure for a disease that affects millions across the globe.

Created in 2012, the ASN Foundation for Kidney Research established a 5-year fundraising goal of $20 million. Already the Foundation has raised more than $14 million, reflecting the urgent need to improve kidney health worldwide.

Responding to the challenge to make an extraordinary difference in kidney care, Founding Members of the ASN Foundation for Kidney Research contributed generously to this exciting new endeavor. A lead $10 million gift from Fresenius Medical Care established the Ben J. Lipps Research Fellowship Program. "Dr. Lipps's professional achievements exemplify the ability of scientists to apply creativity and innovation to advance patient care," said ASN President Ronald J. Falk, MD, FASN.

Additional contributions from Amgen, Baxter International Inc, and ASN rounded out the early success of the Foundation, and established the following fellowships to help advance to a cure for kidney diseases worldwide.

• Five Ben J. Lipps Research Fellows, named for Fresenius Medical Care's CEO and Chairman of the Management Board (1999 - 2012)
• One Sharon Anderson Research Fellow, named for ASN's first female president, funded by ASN
• One Dimitrios G. Oreopoulos Research Fellow, named for one of the pioneers of peritoneal dialysis, funded by Baxter International Inc
• One George B. Rathmann Research Fellow, named for the founding CEO of Amgen and an innovator in biotechnology, funded by Amgen
• Two ASN Foundation for Kidney Research Fellows (to be named)

"These key contributions from founding members will create new frontiers of learning and achievement, and enable all of us improve the lives of kidney patients as we move closer to a cure," said Dr. Falk.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 20). American Society of Nephrology establishes new foundation. News-Medical. Retrieved on April 19, 2024 from https://www.news-medical.net/news/20121026/American-Society-of-Nephrology-establishes-new-foundation.aspx.

  • MLA

    Baxter International Inc.. "American Society of Nephrology establishes new foundation". News-Medical. 19 April 2024. <https://www.news-medical.net/news/20121026/American-Society-of-Nephrology-establishes-new-foundation.aspx>.

  • Chicago

    Baxter International Inc.. "American Society of Nephrology establishes new foundation". News-Medical. https://www.news-medical.net/news/20121026/American-Society-of-Nephrology-establishes-new-foundation.aspx. (accessed April 19, 2024).

  • Harvard

    Baxter International Inc.. 2019. American Society of Nephrology establishes new foundation. News-Medical, viewed 19 April 2024, https://www.news-medical.net/news/20121026/American-Society-of-Nephrology-establishes-new-foundation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial